{"links":{"html":"https://www.erudio.com/reports/va-starport-nct04787744","json":"https://www.erudio.com/reports/va-starport-nct04787744.json","markdown":"https://www.erudio.com/reports/va-starport-nct04787744.md","mcp":{"server":"https://mcp.erudio.com/free","tool":"get_report_card","arguments":{"slug":"va-starport-04787744"}},"request":"https://www.erudio.com/contact?report=va-starport-04787744"},"offer":{"cited_commentary_sources":25,"verified_hcp_statements":119,"currency":"USD","delivery":{"checkout":"online","current_edition":"Emailed as soon as payment clears: downloads, a license key and a prompt that connects your AI agent through Erudio MCP. One key per email address holds every report bought with it.","refresh":"A purchase starts a check for new commentary. A new edition, if one results, is sent to the buyer at no charge."},"identities":{"adds":"Verified IDs for the clinicians in the report, led by the NPI, so a Medical Affairs team can connect the report's voices to the expert and insight records it keeps by NPI: also X, Bluesky, LinkedIn and web pages, ORCID and OpenAlex where verified, inline on each person card (identifiers.status included). Without the add-on, each card's identifiers.status says whether the person is verified. For scientific and insight use inside the organization, including non-promotional engagement such as advisory boards and scientific exchange under its own compliance process; not for promotional targeting. Every report already names and describes its speakers and includes CMS-reported financial relationships. Sample: https://www.erudio.com/report-sample.json","available_with":"12-month updates","cap_usd":750,"identity_verified_people":33,"optional":true,"price_per_verified_person_usd":15,"price_usd":495,"product":"updates-12-identities","terms":"Priced on the identity-verified people in the edition at purchase; people verified later in the term come at no charge."},"one_off_usd":750,"purchase":{"agents":{"free_mcp":"https://mcp.erudio.com/free","keys":"One license key holds every report: get_order returns it once paid (store it as a secret), send it as licence_key with every later create_order so new reports join it. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST /api/keys/recover) with the buyer's email sends it again.","mcp_flow":["1. search_reports: Find reports by trial, NCT ID, drug, indication or sponsor. Each result has its page URL and price.","2. get_report_card: Preview one report with the slug from search_reports: what it covers, its findings and limits, and the price of each product.","3. create_order: Order the current edition or weekly updates for your person. It returns the quote, a checkout_url for your person to pay by card and, when offered, a pay_url your own payment client can pay over HTTP 402 (MPP or x402). Nothing is charged until one is paid.","4. get_order: Once the order is paid, it returns the license key. Store the key as a secret and send it as licence_key with every later create_order, so one key holds every report.","5. read_report: Read the report in full or by section on https://mcp.erudio.com/mcp, with the key as Authorization: Bearer. get_report_changes shows what a newer edition changed."],"order_endpoint":"https://www.erudio.com/api/orders","order_request":{"buyer_email":"name@company.com","idempotency_key":"optional, one per purchase","licence_key":"optional: your key from an earlier purchase","organization":"optional","product":["edition","updates-3","updates-6","updates-12","updates-12-identities"],"report":"va-starport-nct04787744"},"steps":"Create the order (with licence_key if you hold one) and show checkout_url to your person to pay by card. If the order also returns pay_url, you can pay it yourself instead: POST pay_url answers 402 Payment Required with MPP or x402 offers for your payment client. Once paid, status_url (or get_order) returns the license key, the MCP setup and downloads."},"contact":{"email":"hello@erudio.com","form":"https://www.erudio.com/contact?report=va-starport-04787744","people":"Audun Utengen and Tom Lee, the founders","use_for":"Questions, invoices, purchase orders"},"methods":["card (Stripe Checkout)"],"people":"https://www.erudio.com/reports/va-starport-nct04787744","renewal":"Subscriptions are prepaid and do not renew automatically.","upgrades":"What the buyer already paid on this trial counts toward a longer plan: a one-off edition within 30 days, or an active plan at any time in its term. The buyer pays the difference; an upgraded plan keeps its original start, and an upgraded one-off starts the plan on payment. Order the longer product with create_order and the buyer's licence_key (or on the report page with the buyer's email); the quote shows the credit.","terms":"https://www.erudio.com/terms"},"size":"focused","size_rule":"Focused: 1–150 verified statements","updates_usd":{"3_months":1300,"6_months":1900,"12_months":2600},"volume_discounts":[{"min_subscribed_trials":10,"percent_off_updates":25},{"min_subscribed_trials":5,"percent_off_updates":15}]},"publication_state":"public","record":{"change":{"changed_finding_ids":{"reason":"No changed finding IDs recorded.","status":"none"},"last_checked_at":"2026-10-29T20:51:00.415511Z","notify_subscribers":false,"status":"corrected","summary":"Corrected to match the delivered report: per-finding counts; the limitations; the sample findings. The trial is also known as STARPORT. The page names the trial's tested drugs (none) and indication (oligometastatic prostate cancer)."},"contents":{"aspect_coverage":{"assessment_incomplete":0,"discussed":14,"no_commentary_found":0},"aspects":[{"claim_count":3,"coverage":"discussed","id":"T1","registry_field":"outcomesModule.primaryOutcomes[0]","source_count":2,"title":"Primary endpoint: Castration-resistant prostate cancer-free survival (CRPC-free survival)"},{"claim_count":2,"coverage":"discussed","id":"T2","registry_field":"outcomesModule.secondaryOutcomes","source_count":1,"title":"Secondary endpoints"},{"claim_count":8,"coverage":"discussed","id":"T3","registry_field":"conditionsModule","source_count":5,"title":"Population and setting"},{"claim_count":20,"coverage":"discussed","id":"T4","registry_field":"armsInterventionsModule.armGroups","source_count":6,"title":"The comparison"},{"claim_count":12,"coverage":"discussed","id":"T5","registry_field":"outcomesModule","source_count":2,"title":"Safety and tolerability"},{"claim_count":14,"coverage":"discussed","id":"T6","registry_field":"designModule","source_count":9,"title":"Design and conduct"},{"claim_count":14,"coverage":"discussed","id":"A1","source_count":1,"title":"Nodal treatment extent, adjacent recurrence and retreatment"},{"claim_count":10,"coverage":"discussed","id":"A2","source_count":5,"title":"PSMA PET, metastatic burden and molecular selection"},{"claim_count":16,"coverage":"discussed","id":"A3","source_count":1,"title":"Biological skepticism and cross-cancer extrapolation"},{"claim_count":11,"coverage":"discussed","id":"A4","source_count":5,"title":"SATURN, SOLAR, EXTEND, GU011 and WOLVERINE as evidence around the VA STARPORT question"},{"claim_count":14,"coverage":"discussed","id":"A5","source_count":1,"title":"Clinician equipoise, recruiter training and recruitment resources"},{"claim_count":14,"coverage":"discussed","id":"A6","source_count":2,"title":"Recruitment language, family counseling and shared treatment decisions"},{"claim_count":8,"coverage":"discussed","id":"A7","source_count":8,"title":"Veteran access, participating sites and multidisciplinary care"},{"claim_count":7,"coverage":"discussed","id":"A8","source_count":2,"title":"Anticipated practice impact, study size and data maturity"}],"counts":{"cited_sources":26,"claims_by_expression_type":{"comparison":11,"experience":12,"interpretation":24,"opinion":28,"primary_context":1,"question":12,"restatement":17,"uncertainty":8,"unspecified":6},"claims_by_kind":{"protocol_statement":1,"source_observation":118},"clinician_statements":72,"evidence_units":130,"findings":11,"organisational_accounts":1,"people_cited":36,"people_identity_verified":33,"people_total":37,"screened_sources":47,"verified_claims":119},"findings_index":[{"id":"F1","structure":{"claims":20,"claims_by_group":{"comparisons":0,"experience":0,"questions":6,"restated":5,"views":9},"has_counterview":true,"limitations":2,"links":{"context":1,"support":21},"ma_question":true,"named_voices":8,"passages":15,"sources":6,"sources_by_kind":{"commentary":4,"media":1,"registry":1}},"title":"The unresolved decision is whether local therapy adds to systemic care—not whether it can replace systemic care"},{"id":"F2","structure":{"claims":7,"claims_by_group":{"comparisons":0,"experience":0,"questions":2,"restated":3,"views":2},"has_counterview":true,"limitations":2,"links":{"context":0,"support":7},"ma_question":true,"named_voices":4,"passages":6,"sources":5,"sources_by_kind":{"commentary":4,"registry":1}},"title":"Endpoint credibility is challenged by the possibility that MDT changes PSA without establishing broader disease control"},{"id":"F3","structure":{"claims":14,"claims_by_group":{"comparisons":4,"experience":2,"questions":3,"restated":4,"views":1},"has_counterview":true,"limitations":2,"links":{"context":0,"support":14},"ma_question":true,"named_voices":6,"passages":14,"sources":1,"sources_by_kind":{"commentary":1}},"title":"Focal SBRT versus elective nodal treatment remains disputed, and VA STARPORT does not randomize that choice"},{"id":"F4","structure":{"claims":9,"claims_by_group":{"comparisons":0,"experience":1,"questions":2,"restated":2,"views":4},"has_counterview":true,"limitations":2,"links":{"context":0,"support":9},"ma_question":true,"named_voices":5,"passages":9,"sources":1,"sources_by_kind":{"commentary":1}},"title":"Safety arguments depend on treatment volume and evidence type; focal nodal SBRT is not large-field five-fraction treatment"},{"id":"F5","structure":{"claims":18,"claims_by_group":{"comparisons":3,"experience":2,"questions":2,"restated":2,"views":9},"has_counterview":true,"limitations":2,"links":{"context":1,"support":18},"ma_question":true,"named_voices":12,"passages":19,"sources":1,"sources_by_kind":{"commentary":1}},"title":"The prostate MDT question includes strong biological skepticism, but cross-cancer generalization is contested"},{"id":"F6","structure":{"claims":13,"claims_by_group":{"comparisons":1,"experience":0,"questions":0,"restated":6,"views":6},"has_counterview":true,"limitations":3,"links":{"context":4,"support":14},"ma_question":true,"named_voices":5,"passages":14,"sources":6,"sources_by_kind":{"commentary":6}},"title":"Favorable intermittent-therapy and pooled-MDT interpretations remain distinct from VA STARPORT efficacy"},{"id":"F7","structure":{"claims":11,"claims_by_group":{"comparisons":1,"experience":1,"questions":4,"restated":1,"views":4},"has_counterview":true,"limitations":2,"links":{"context":1,"support":11},"ma_question":true,"named_voices":8,"passages":12,"sources":6,"sources_by_kind":{"commentary":5,"registry":1}},"title":"Imaging and molecular biology are proposed as better selection tools, but neither is established here as a replacement for counting metastases"},{"id":"F8","structure":{"claims":14,"claims_by_group":{"comparisons":1,"experience":2,"questions":2,"restated":2,"views":7},"has_counterview":true,"limitations":2,"links":{"context":0,"support":14},"ma_question":true,"named_voices":7,"passages":14,"sources":1,"sources_by_kind":{"commentary":1}},"title":"Recruitment difficulty is attributed to clinician preferences as well as labor, support and patient-care trade-offs"},{"id":"F9","structure":{"claims":14,"claims_by_group":{"comparisons":0,"experience":2,"questions":1,"restated":3,"views":8},"has_counterview":true,"limitations":2,"links":{"context":2,"support":16},"ma_question":true,"named_voices":3,"passages":10,"sources":2,"sources_by_kind":{"commentary":1,"media":1}},"title":"Recruitment wording is contested, with family conversations and shared decisions offered as safeguards"},{"id":"F10","structure":{"claims":8,"claims_by_group":{"comparisons":0,"experience":3,"questions":0,"restated":0,"views":5},"has_counterview":false,"limitations":2,"links":{"context":1,"support":8},"ma_question":true,"named_voices":4,"passages":9,"sources":8,"sources_by_kind":{"commentary":7,"media":1}},"title":"Trial access and multidisciplinary care are valued separately from any eventual MDT treatment effect"},{"id":"F11","structure":{"claims":7,"claims_by_group":{"comparisons":2,"experience":0,"questions":2,"restated":0,"views":3},"has_counterview":false,"limitations":2,"links":{"context":0,"support":7},"ma_question":true,"named_voices":4,"passages":7,"sources":2,"sources_by_kind":{"commentary":2}},"title":"Anticipation is emphatic, but speakers still condition clinical impact on mature results"}],"medical_affairs_question":"How should teams explain uncertain incremental benefit and differing local-treatment choices without implying that one randomized group is already inferior?","sections":{"analysis":[{"id":"section-1","level":2,"title":"Adding local therapy: an unresolved benefit on top of systemic care"},{"id":"section-2","level":2,"title":"Endpoint meaning: PSA effects versus radiographic and clinical progression"},{"id":"section-3","level":2,"title":"Nodal treatment extent: convenience, adjacent failure and a nonrandomized technique comparison"},{"id":"section-4","level":2,"title":"Safety: distinguish focal nodes from large elective volumes"},{"id":"section-5","level":2,"title":"Biological skepticism and the limits of cross-cancer extrapolation"},{"id":"section-6","level":2,"title":"Favorable signals from intermittent treatment and WOLVERINE are not VA STARPORT results"},{"id":"section-7","level":2,"title":"Selection: imaging sensitivity, counts and molecular information"},{"id":"section-8","level":2,"title":"Recruitment: clinician influence, resources and preference-sensitive care"},{"id":"section-9","level":2,"title":"Recruitment language and the patient-support conversation"},{"id":"section-10","level":2,"title":"Access and multidisciplinary value apart from efficacy"},{"id":"section-11","level":2,"title":"Anticipated influence remains conditional on mature evidence"},{"id":"section-12","level":2,"title":"Scope and coverage"}],"executive_summary":{"reason":"Reviewed narrative has no headings.","status":"unavailable"}},"study_design":"interventional, randomized, parallel, phase2, phase3","trial_dimensions":[{"findings":[{"id":"F2","shared_claims":3}],"id":"T1","label":"Primary endpoint: Castration-resistant prostate cancer-free survival (CRPC-free survival)"},{"findings":[{"id":"F2","shared_claims":2}],"id":"T2","label":"Secondary endpoints"},{"findings":[{"id":"F1","shared_claims":1},{"id":"F6","shared_claims":1},{"id":"F7","shared_claims":5},{"id":"F9","shared_claims":1},{"id":"F10","shared_claims":1},{"id":"F11","shared_claims":2}],"id":"T3","label":"Population and setting"},{"findings":[{"id":"F1","shared_claims":16},{"id":"F3","shared_claims":2},{"id":"F5","shared_claims":2},{"id":"F6","shared_claims":2},{"id":"F9","shared_claims":5}],"id":"T4","label":"The comparison"},{"findings":[{"id":"F1","shared_claims":1},{"id":"F3","shared_claims":1},{"id":"F4","shared_claims":9},{"id":"F9","shared_claims":2}],"id":"T5","label":"Safety and tolerability"},{"findings":[{"id":"F1","shared_claims":4},{"id":"F2","shared_claims":2},{"id":"F3","shared_claims":2},{"id":"F6","shared_claims":1},{"id":"F8","shared_claims":1},{"id":"F9","shared_claims":2},{"id":"F10","shared_claims":1},{"id":"F11","shared_claims":3}],"id":"T6","label":"Design and conduct"}]},"identity":{"accepted_at":"2026-10-29T20:51:00.415511Z","edition_number":1,"previous_run_id":{"reason":"First accepted catalog edition.","status":"not_applicable"},"previous_version":{"reason":"First accepted catalog edition.","status":"not_applicable"},"product_contract":"hcp-commentary-1","published_at":"2026-10-29T21:03:19Z","record_hash":"4abc8adfa608673eb537bfb02edcb1bb97bd33f19d3916cd80f9552ec3a29231","release_hash":"eded92fb63ec2baa9881259cbc369b83dafe21255694e467932655d1bfd24f00","report_id":"erudio-nct04787744","run_id":"3591e320-34d2-45ed-aa62-33ecbac74802","schema_version":"5.0","slug":"va-starport-04787744","version":"1.0.0","version_reason":"initial"},"offer":{"bundle_eligible":{"reason":"Owner has not set bundle_eligible.","status":"not_set"},"license_ref":{"reason":"Owner has not set license_ref.","status":"not_set"},"request_route":{"reason":"Owner has not set request_route.","status":"not_set"},"single_edition":{"reason":"Owner has not set single_edition.","status":"not_set"},"updates":{"reason":"Owner has not set updates.","status":"not_set"}},"preview":{"abstract":"VA STARPORT asks whether adding PET-directed local treatment to systemic therapy delays castration resistance in Veterans with oligometastatic prostate cancer. In an X exchange, a poster challenges the preference for focal rather than elective nodal treatment. An X poster welcomes multicenter VA research, while an X poster questions endpoint interpretation. The incremental benefit of local treatment and the trial’s eventual influence on practice remain unresolved.","meta_description":"47 sources screened · 119 verified statements (72 from clinicians verified by NPI or staff page) from 26 sources · 11 findings. Updated Oct 29, 2026.","person_names_policy":"role_only","sample_findings":[{"cited_claim_ids":["claim-e812ca32e681975533f1"],"id":"F2","paraphrase":"An X-thread post asks which assumptions were used to determine VA STARPORT’s sample size.","source_channel":"x_thread","source_date":{"reason":"The thread includes posts dated 2021-02-25 and 2021-04-06; the question’s individual post date is not specified.","status":"unavailable"},"title":"Endpoint credibility is challenged by the possibility that MDT changes PSA without establishing broader disease control"},{"cited_claim_ids":["claim-089e49be914919f1a635","claim-b84fb39f6b6a27342f8e"],"id":"F7","paraphrase":"In an X thread that names VA STARPORT, a post asks whether molecular markers might replace metastasis counts when selecting treatment.","source_channel":"x_thread","source_date":"2022-03-29","title":"Imaging and molecular biology are proposed as better selection tools, but neither is established here as a replacement for counting metastases"}]},"publication":{"approved_at":"2026-10-29T21:03:19Z","approved_by":"Erudio publisher","corrections":[{"affected_ids":[],"date":"2026-10-29T22:21:17Z","summary":"Corrected to match the delivered report: per-finding counts; the limitations; the sample findings. The trial is also known as STARPORT. The page names the trial's tested drugs (none) and indication (oligometastatic prostate cancer)."}],"rights_status":"cleared: short attributed excerpts with link-out; no-derivatives sources suppressed; role-only names in previews","state":"public"},"schema_id":"erudio.catalog_record","schema_version":"2.1","scope_and_limits":{"commentary_scope":{"basis":"Only the sources used in this report; not all HCPs or all public discussion.","has_known_gaps":true,"source_count":47},"does_not":["judge efficacy","estimate HCP prevalence or consensus","give treatment advice"],"known_gaps":["Discussion that does not name the trial may be missing from this edition.","Some clinician views in the sources used in this report are not yet captured as evidence in this edition.","Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.","61 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.","Further source limits apply, so some matching discussion may be missing.","No full VA STARPORT protocol or trial-specific results publication is included. Speakers’ explanations of planned conduct, possible adaptations and expected benefit should not be treated as completed analyses or confirmed treatment effects.","Some potentially relevant passages were not fully assessed. Discussion that never named VA STARPORT, used alternative spellings or wording, or preceded registration may be underrepresented.","The reviewed public discussion does not establish the prevalence of any view among HCPs. Reposts and repeated posts are not additional independent clinical opinions.","Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.","A speaker is described in the source as involved in VA STARPORT. The trial explanations and operational observations should not be counted as independent external validation.","Statements about other trials preserve their own populations, regimens and outcomes. In particular, breast-cancer findings, intermittent-treatment PSA observations and mixed-castration-status pooled results are not VA STARPORT results.","Source dates span 2020–2026. Site counts, enrollment observations, anticipated timelines and expectations of practice impact are dated statements, not confirmation of current status.","No exact regulatory labels for several grouped systemic-treatment options were available in the reviewed material. The report does not establish label-specific eligibility or prescribing conclusions.","Not yet captured in this edition: a view on metastasis-directed therapy in oligorecurrent prostate cancer and the need for stronger evidence across survival endpoints.","Not yet captured in this edition: a view on restricted access to PSMA PET imaging for PET-directed treatment decisions."]},"sources":{"cited_sources":{"by_channel":{"bluesky_thread":0,"linkedin_post":0,"other":0,"podcast":0,"publication":0,"registry":1,"regulatory":0,"x_thread":24,"x_video":0,"youtube":1},"by_evidence_role":{"commentary":25,"methods":1},"count":26,"evidence_window":{"end":"2026-10-08","start":"2020-11-29"},"retrieval_snapshot":"2026-10-29T19:48:06.113933Z","timeline":[{"count":1,"week":"2020-W48"},{"count":1,"week":"2020-W49"},{"count":1,"week":"2021-W14"},{"count":1,"week":"2021-W21"},{"count":3,"week":"2021-W23"},{"count":1,"week":"2021-W24"},{"count":1,"week":"2021-W25"},{"count":1,"week":"2021-W30"},{"count":1,"week":"2021-W37"},{"count":1,"week":"2021-W49"},{"count":1,"week":"2022-W13"},{"count":1,"week":"2022-W20"},{"count":1,"week":"2022-W21"},{"count":1,"week":"2022-W23"},{"count":1,"week":"2022-W27"},{"count":1,"week":"2022-W28"},{"count":1,"week":"2022-W41"},{"count":1,"week":"2024-W12"},{"count":1,"week":"2024-W16"},{"count":1,"week":"2024-W32"},{"count":1,"week":"2024-W47"},{"count":3,"week":"2025-W07"},{"count":1,"week":"2025-W34"},{"count":1,"week":"2026-W41"}],"undated_sources":1},"quote_policies":[{"id":"clinicaltrials:NCT04787744:methods","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT04787744:context","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1333089511736283138:d39dabc9-2491-4064-a1be-dbc57b81b6b1","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1333945804260782080:da506116-8813-4444-9b78-bfaa06f901be","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1364955051643568134:88f6f496-076e-446b-a8b5-1c60f0c6c1bf","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1370757525675462662:6f5adc2c-e86d-46c8-aaaf-f3d343e7ad7e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1398676128836038660:ed47ea42-3ce6-44c6-8a90-7351cf0184a0","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1403369033966161920:198cea6a-1020-42e1-890d-35f06ec38911","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1403436601183719424:c74f5309-a2ba-4ab3-bf07-ee8ec37a0bf5","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1403504227746516993:45817032-1012-424b-a5e8-99aa9e229e15","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1404522797280288771:3cfd6d69-03a2-414c-bcb0-8d933c08d7fe","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1420550176532480001:c907a39b-4c64-40b2-9bec-47c79f8f5fa5","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1427256523219218433:3836de49-ba0e-4cd2-bf35-c65d67cc3040","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1427346423696302080:2d001971-52b4-40bd-9c2b-8c9b4b6169ae","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1427455152680808452:1f7fd685-fde2-4fc4-be85-d59039337348","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1427709321450868747:47629613-f109-495d-8ca8-9c18512012e8","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1429613106607529989:72468037-d20d-4d6e-8f51-a3d5b2cbb529","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1437510382575177728:91cc85ad-230f-4145-935f-5c8762a8a4b4","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1468764681116528643:1f33405b-900f-4838-8b41-7a11994423b8","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1494545881634607106:5c29970b-443a-433e-b0d8-50114d400799","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1494707054451507200:fa175f4a-e3d6-40b5-a80e-3d60b851c1be","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1508923423187120129:1a0e1894-7f0a-45e7-a758-c5bf252f6440","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1509668848961687565:0f390a72-d4ba-46e5-a40f-c3ed5e20206a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1525100008667766787:8d85f89d-9504-4e4e-9dff-d339bc36e365","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1528089485514137600:f5372762-8ba3-4507-8f4e-488240b7b462","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1533880124608847881:4d49e908-876b-4362-9b09-45e721f18382","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1533946333559771137:bb3679f6-add3-4ecc-95aa-996d4b3ce59e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1534372103675338752:f9f41dd3-661d-4e9b-918b-bd2f243b0a43","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1545505546870161410:b27a12f4-2d65-458d-b95f-76be3a37b337","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1549152843390541825:810e1bd3-2a88-49a7-a637-0fdd8b4af855","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1580182210019135488:f9546fea-ff9e-4a89-a0a9-49c4cd6252db","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1672609449171726338:20bb31df-2fa1-4073-bd99-467fe56a87be","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1680816180465119236:feed91fa-94e9-424b-89b5-21c63488a2e4","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1770342366039126523:9cba6dfa-f082-4a35-8cf0-02926e7e4b9e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1779879854865002955:fa0e1af1-a389-413b-9b49-bdde3da06a13","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1797268622529765722:21af2b07-3580-4b85-baf4-8c6f554e3b6c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1797270695841616004:7d5e0df7-27f3-430b-899e-4f6bd30e4a4f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1797334967598358655:3ea4103f-300f-4007-8c56-0b5e7c902ff9","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1797621631139140068:3b94c72e-377d-4245-aa4b-b15d20275198","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1797621728140763182:49b6e45f-1437-46cf-8edf-4330c139b3ab","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1826631429863956500:1a9db548-7282-4cfb-91b0-dad72474f5a1","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1859431961548234819:3b04d984-071e-4b8f-a818-76b31cb067ef","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1890184719553425551:7241cb00-58f7-457d-bdad-c7f98de1e167","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1890186546244100336:284d80af-9610-4c70-bed3-b60967845c00","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1890186682034761853:31facc5e-fe8a-423b-982c-b5dc45f19fa7","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1958227599496233154:68d47f3e-7c58-44f1-8496-f44502119c3f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1991272110057259247:5067c9d5-e72b-401b-9df9-1c2f271b76fd","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2107153845390286898:cb2af548-9534-4c01-a87b-d3285862a437","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:s4fLvZ-HtS0","quote_policy":"short_quote_link_out"}],"screened_sources":{"by_channel":{"bluesky_thread":0,"linkedin_post":0,"other":0,"podcast":0,"publication":0,"registry":0,"regulatory":0,"x_thread":46,"x_video":0,"youtube":1},"by_evidence_role":{"commentary":47},"count":47,"evidence_window":{"end":"2026-10-08","start":"2020-11-29"},"retrieval_snapshot":"2026-10-29T19:48:06.113933Z","timeline":[{"count":1,"week":"2020-W48"},{"count":1,"week":"2020-W49"},{"count":1,"week":"2021-W10"},{"count":1,"week":"2021-W14"},{"count":1,"week":"2021-W21"},{"count":3,"week":"2021-W23"},{"count":1,"week":"2021-W24"},{"count":1,"week":"2021-W25"},{"count":1,"week":"2021-W30"},{"count":4,"week":"2021-W33"},{"count":1,"week":"2021-W34"},{"count":1,"week":"2021-W37"},{"count":1,"week":"2021-W49"},{"count":2,"week":"2022-W07"},{"count":2,"week":"2022-W13"},{"count":1,"week":"2022-W19"},{"count":1,"week":"2022-W20"},{"count":1,"week":"2022-W21"},{"count":3,"week":"2022-W23"},{"count":1,"week":"2022-W27"},{"count":1,"week":"2022-W28"},{"count":1,"week":"2022-W29"},{"count":1,"week":"2022-W41"},{"count":1,"week":"2023-W25"},{"count":1,"week":"2023-W29"},{"count":1,"week":"2024-W12"},{"count":1,"week":"2024-W16"},{"count":3,"week":"2024-W22"},{"count":2,"week":"2024-W23"},{"count":1,"week":"2024-W32"},{"count":1,"week":"2024-W35"},{"count":1,"week":"2024-W47"},{"count":3,"week":"2025-W07"},{"count":1,"week":"2025-W34"},{"count":1,"week":"2025-W47"},{"count":1,"week":"2026-W41"}],"undated_sources":0}},"taxonomy":{"biomarkers":{"reason":"No structured, checked-in biomarker mapping for this trial.","status":"unmapped"},"conferences":{"reason":"No conferences in source metadata.","status":"none"},"drugs":[{"reason":"Unmapped registry intervention: salvage local therapy for locally recurrent disease","status":"unmapped"},{"reason":"Unmapped registry intervention: goserelin, histrelin, leuprolide & triptorelin","status":"unmapped"},{"reason":"Unmapped registry intervention: adt + nilutamide, flutamide, & bicalutamide","status":"unmapped"},{"reason":"Unmapped registry intervention: degarelix & relugolix","status":"unmapped"},{"reason":"Unmapped registry intervention: adt + docetaxel +/- prednisone","status":"unmapped"},{"reason":"Unmapped registry intervention: adt + abiraterone + prednisone","status":"unmapped"},{"reason":"Unmapped registry intervention: adt + abiraterone + methylprednisolone","status":"unmapped"},{"reason":"Unmapped registry intervention: adt + apalutamide","status":"unmapped"},{"reason":"Unmapped registry intervention: adt + enzalutamide","status":"unmapped"}],"indications":[{"brand_names":{"reason":"Indication, not a drug.","status":"not_applicable"},"label":"Prostate cancer","slug":"prostate-cancer"},{"reason":"Unmapped registry condition: Oligometastasis","status":"unmapped"},{"reason":"Unmapped registry condition: Oligorecurrence","status":"unmapped"},{"reason":"Unmapped registry condition: Recurrent Prostate Cancer","status":"unmapped"},{"reason":"Unmapped registry condition: De Novo Prostate Cancer","status":"unmapped"}],"line_of_therapy":{"reason":"No structured, checked-in line-of-therapy mapping for this trial.","status":"unmapped"},"therapeutic_area":["oncology"]},"trial":{"acronym":"VA STARPORT","aliases":["VA STARPORT","Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer","Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for OligoRecurrenT Prostate Cancer (VA STARPORT)"],"brief_title":"Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer","collaborators":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"conditions":["Prostate Cancer","Oligometastasis","Oligorecurrence","Recurrent Prostate Cancer","Metastatic Prostate Cancer","De Novo Prostate Cancer"],"display_condition":"oligometastatic prostate cancer","display_interventions":[],"enrollment":{"count":378,"type":"ACTUAL"},"interventions":[{"name":"PET-directed Local Therapy using Surgery","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"PROCEDURE"},{"name":"PET-directed Local Therapy using Radiation","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"RADIATION"},{"name":"Salvage Local Therapy for locally recurrent disease","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"OTHER"},{"name":"Goserelin, Histrelin, Leuprolide & Triptorelin","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"ADT + Nilutamide, Flutamide, & Bicalutamide","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"Degarelix & Relugolix","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"ADT + Docetaxel +/- prednisone","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"ADT + Abiraterone + Prednisone","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"ADT + Abiraterone + Methylprednisolone","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"ADT + Apalutamide","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"ADT + Enzalutamide","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"Prostate-directed Radiation for De novo oligometastatic prostate cancer","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"RADIATION"}],"nct_id":"NCT04787744","official_title":"Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for OligoRecurrenT Prostate Cancer (VA STARPORT)","other_names":[{"kind":"also","name":"STARPORT"}],"overall_status":"ACTIVE_NOT_RECRUITING","phase":["PHASE2","PHASE3"],"primary_completion_date":{"date":"2026-10-02","type":"ACTUAL"},"primary_endpoints":[{"description":"CRPC-free survival is a time-to-event outcome defined as the length of time from randomization to the first occurrence of failure. The following are forms of failure in the setting of a castrate testosterone level: PSA progression, radiographic progression, symptomatic skeletal event due to progression, and death.","measure":"Castration-resistant prostate cancer-free survival (CRPC-free survival)","timeFrame":"4 years"}],"registered_date":{"date":"2021-03-09","type":"ACTUAL"},"registry_last_updated":"2026-10-19","registry_url":"https://clinicaltrials.gov/study/NCT04787744","short_name":"VA STARPORT","short_name_basis":"registry_acronym","sponsor":"VA Office of Research and Development","start_date":{"date":"2021-07-01","type":"ACTUAL"},"study_design":"interventional, randomized, parallel, phase2, phase3","study_ids":[{"id":"ONCA-026-20S","type":"sponsor_study_id"},{"id":"1I01CX002277-01","type":"nih"},{"domain":"VA Investigators, Scientific Review and Management","id":"CX002277-01","type":"other_grant"}],"study_type":"INTERVENTIONAL"}}}